TL;DR
This study investigates the therapeutic mechanisms of Biejiajian Pill (BJJP), a traditional Chinese medicine, for diabetic atherosclerosis. By combining network pharmacology, molecular docking, and molecular dynamics simulations, the researchers identified key active compounds and molecular targets, revealing BJJP's multi-component, multi-target, and multi-pathway approach to treating this complex condition.
What Problem Does This Paper Address?
Diabetic atherosclerosis is a serious complication of diabetes, characterized by a high incidence, rapid progression, and widespread organ involvement. Current single-target therapies are insufficient to combat its complex pathological mechanisms. Biejiajian Pill (BJJP), a traditional Chinese medicine formula, has shown promise in treating diabetic atherosclerosis, but its underlying molecular mechanisms remain largely unclear. This research aims to elucidate these mechanisms, providing a scientific basis for BJJP's clinical application and guiding future research.
Methods
The study employed a multi-pronged computational approach:
- Network Pharmacology: This involved screening active compounds from BJJP using databases like TCMSP and TCMID, predicting their potential targets, and identifying targets associated with diabetic atherosclerosis from GeneCards and OMIM. A protein-protein interaction (PPI) network was constructed using STRING, and key targets were identified using Cytoscape's Network Analyzer. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using DAVID to understand the biological processes and signaling pathways involved.
- Molecular Docking: This technique was used to assess the binding affinity between the identified core active compounds and the key target proteins. AutoDock Vina was employed for docking, and PyMOL was used for visualization.
- Molecular Dynamics (MD) Simulation: To further validate the stability of the molecular interactions predicted by docking, MD simulations were conducted using GROMACS. This provided insights into the dynamic behavior of the compound-target complexes.
Datasets
- Active Compounds and Targets: TCMSP, TCMID, and SwissTargetPrediction databases were used to identify active compounds in BJJP and their corresponding targets.
- Diabetic Atherosclerosis Targets: GeneCards and OMIM databases were queried for genes associated with diabetic atherosclerosis.
- Protein-Protein Interactions: The STRING database was used to construct the PPI network.
- 3D Protein Structures: The RCSB Protein Data Bank was used to retrieve the 3D structures of the key target proteins.
No new benchmarks were introduced; rather, established databases and computational tools were utilized.
Key Insights and Ideas
- Multi-component, Multi-target, Multi-pathway Action: The study strongly suggests that BJJP's efficacy stems from its ability to act on numerous components, targets, and pathways simultaneously, aligning with the holistic principles of traditional Chinese medicine.
- Identification of Core Bioactive Compounds: Quercetin, luteolin, kaempferol, chrysin, and glutamic acid were identified as potential core active compounds due to their high degree values in the network analysis. These are largely flavonoids, known for their antioxidant and anti-inflammatory properties.
- Key Molecular Targets: The research pinpointed several crucial protein targets, including AKT1, EGFR, SRC, STAT3, PPARG, ESR1, MMP9, PIK3R1, and AR, which are implicated in various aspects of diabetic atherosclerosis.
- Enrichment in Key Biological Processes and Pathways: GO analysis highlighted involvement in oxidation-reduction, negative regulation of apoptosis, and inflammatory response. KEGG analysis pointed to significant roles in pathways like PPAR signaling, insulin resistance, and HIF-1 signaling.
Key Results
- 81 active compounds and 186 potential targets for BJJP were identified.
- 121 overlapping targets were found between BJJP's targets and those associated with diabetic atherosclerosis.
- Top nine degree targets identified through PPI network analysis were AKT1, EGFR, SRC, STAT3, PPARG, ESR1, MMP9, PIK3R1, and AR.
- GO enrichment analysis revealed that the common targets are significantly involved in oxidation-reduction processes, negative regulation of apoptotic processes, and inflammatory responses.
- KEGG pathway analysis indicated that common targets primarily participate in pathways such as proteoglycans in cancer, PPAR signaling pathway, adherens junction, insulin resistance, and HIF-1 signaling pathway.
- Molecular docking confirmed good binding affinity between core active compounds and key targets.
- Molecular dynamics simulations showed stable binding models for AKT1-Luteolin, MMP9-Quercetin, and MMP9-Luteolin complexes, with binding energies of -28.93 kJ·mol⁻¹, -37.12 kJ·mol⁻¹, and -62.91 kJ·mol⁻¹, respectively, indicating spontaneous binding.
Limitations and Future Work
The authors acknowledge several limitations of network pharmacology:
- Quantification Challenges: It is difficult to precisely quantify dose-efficacy relationships using current network pharmacology techniques.
- Database Dependency: The analysis relies on existing databases, meaning some compounds and targets might be missing or incompletely represented.
- Static Nature: Network pharmacology provides a static snapshot, whereas disease progression and drug actions are dynamic processes.
The authors suggest that future work should involve in vivo and in vitro experiments to further explore the deeper mechanisms of BJJP in treating diabetic atherosclerosis. This study provides a strong foundation and rationale for such experimental investigations, offering valuable insights for clinical application.
Summary updated